Cargando…

Management of Chronic Myeloid Leukemia in Advanced Phase

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution and development of resistant mutations represent crucial events that limit the benefit of subsequent therapies in these pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonifacio, Massimiliano, Stagno, Fabio, Scaffidi, Luigi, Krampera, Mauro, Di Raimondo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823861/ https://www.ncbi.nlm.nih.gov/pubmed/31709190 http://dx.doi.org/10.3389/fonc.2019.01132

Ejemplares similares

Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity
por: Boni, Christian, et al.
Publicado: (2022)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)

Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia
por: Tomasello, Luisa, et al.
Publicado: (2020)

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib
por: Loscocco, Federica, et al.
Publicado: (2021)

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
por: Specchia, Giorgina, et al.
Publicado: (2021)

Editorial: Advances in the treatment of chronic myeloid leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2023)

The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
por: Massimino, Michele, et al.
Publicado: (2018)

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
por: Giallongo, Cesarina, et al.
Publicado: (2015)

Atypical presentation of patients with chronic myeloid leukemia in chronic phase—Case report
por: Ramdohr, Florian, et al.
Publicado: (2022)

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
por: Borghi, Lidia, et al.
Publicado: (2021)

Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
por: Andretta, Emanuela, et al.
Publicado: (2021)

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
por: Bonifacio, Massimiliano, et al.
Publicado: (2020)

Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2014)

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
por: Jiang, Bo, et al.
Publicado: (2023)

New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
por: Westerweel, Peter E., et al.
Publicado: (2019)

Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2019)

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients
por: Stella, Stefania, et al.
Publicado: (2022)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
por: Tecchio, Cristina, et al.
Publicado: (2023)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective
por: Atallah, Ehab L., et al.
Publicado: (2022)

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020)
por: Wang, Yue, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase
por: Yılmaz, Umut, et al.
Publicado: (2022)

Debating Frontline Therapy in Chronic Myeloid Leukemia
por: Bi, Xia, et al.
Publicado: (2021)

Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2020)

Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
por: Capodanno, Isabella, et al.
Publicado: (2021)

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase
por: Yohanan, Binoy, et al.
Publicado: (2022)

The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
por: Grassi, Susanna, et al.
Publicado: (2019)

Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia
por: Kamga, Paul Takam, et al.
Publicado: (2016)

Editorial: Precision medicine for acute myeloid leukemia
por: Marconi, Giovanni, et al.
Publicado: (2023)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias
por: Bhingarkar, Aboli, et al.
Publicado: (2021)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
por: Caocci, Giovanni, et al.
Publicado: (2019)

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience
por: Chitanava, Tamara, et al.
Publicado: (2023)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
por: Chen, Yilin, et al.
Publicado: (2021)

Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tspfr7o2f23mn4kttc2smbbf8a